

Transforming Cell Line Development with Syngene's SynWeave™ Platform

Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous clones.

The platform integrates advanced clone screening using the Ambr-250 bioreactor, allowing for comprehensive evaluation of titer, key product quality attributes, and process parameters, accelerating your path to robust cell line development.



SynWeave™: Setting a New Standard in Cell Line Development

- 01 Higher Integration Efficiency**
SynWeave™ uses transposon-mediated integration for reliable and efficient gene insertion, addressing low integration rates.
- 02 Reduced Heterogeneity**
SynWeave™ minimizes variability, producing uniform, stable clones that yield mixed populations due to position effects.
- 03 Accelerated Development Timeline**
SynWeave™ enables rapid progression to clinical and commercial stages by significantly shortening the development cycle.
- 04 Enhanced Product Quality**
SynWeave™ selects high-yield clones with consistent quality based on rigorous titer and product assessments.
- 05 Reliable Outcomes**
SynWeave™ delivers consistent results from the outset, minimizing the need for rework.

For more information, contact bdc@syngeneintl.com
www.syngeneintl.com




Scan the QR code to learn more

9 g/L titer for mAb (IgG)



SynWeave™: Develop Clones in Just 9 Weeks from Transfection



For more information, contact bdc@syngeneintl.com
www.syngeneintl.com



Scan the QR code to learn more